Preclinical study demonstrates ligand-mediated lipid reprogramming redirects liver-tropic nanoparticles to the lungs, indicating improved efficacy for pulmonary mRNA delivery and genome editing.
In Research Article e6080664, Lulu Xue and co-workers present a ligand-mediated lipid reprogramming strategy that redirects liver-tropic ionizable lipids toward lung-selective mRNA delivery. Site-specific installation of small-molecule ligands onto the headgroup of the 2-t6b ionizable lipid enables precise organ retargeting while preserving the parent scaffold, resulting in markedly enhanced efficacy for lung-targeted mRNA delivery and genome editing applications.
No takes yet. Share an insight, caveat, or question.
顾竹笑 et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: